Annotation Detail
Information
- Associated Genes
- CDKN2A
- Associated Variants
-
CDKN2A p16 EXPRESSION
CDKN2A p16 EXPRESSION - Associated Disease
- head and neck squamous cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Phase III trial to compare afatinib or metothrexate in recurrent or metastatic head and neck squamous cell carcinoma. 483 patients were randomized to either afatinib (n=322) or methotrexate (n=161). 285 patients were assessed for p16 Status (IHC). In the post-hoc analysis, benefit of afatinib compared with methotrexate was more pronounced in p16-negative disease (HR 0·69 [95% CI 0·50–0·96], p=0.022) than in p16-positive disease (HR 0·95 [CI 0·51–1·75], p=0.67, interaction test p=0·32).
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1155
- Gene URL
- https://civic.genome.wustl.edu/links/genes/14
- Variant URL
- https://civic.genome.wustl.edu/links/variants/272
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Head And Neck Squamous Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Afatinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 25892145
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Afatinib | Resitance or Non-Reponse | true |